Pseudoprogression in patients with uterine leiomyosarcoma treated with first-line single-agent doxorubicin.

[1]  F. Bertucci,et al.  Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. , 2022, The Lancet. Oncology.

[2]  F. Yıldız,et al.  The Need for Effective Adjuvant Therapy in Uterine Leiomyosarcoma: A Single-centre Experience. , 2021, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[3]  A. B. Hassan,et al.  Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  A. Gronchi,et al.  Soft‐tissue sarcoma in adults: An update on the current state of histiotype‐specific management in an era of personalized medicine , 2020, CA: a cancer journal for clinicians.

[5]  Robin L. Jones,et al.  Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial. , 2020, JAMA.

[6]  C. Beigelman,et al.  Imaging of tumour response to immunotherapy , 2020, European Radiology Experimental.

[7]  Jinming Yu,et al.  The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy , 2019, Cancer biology & medicine.

[8]  M. Horger,et al.  CT-response patterns and the role of CT-textural features in inoperable abdominal/retroperitoneal soft tissue sarcomas treated with trabectedin. , 2018, European journal of radiology.

[9]  D. Jamieson,et al.  Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial , 2017 .

[10]  Robin L. Jones,et al.  Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. , 2017, The Lancet. Oncology.

[11]  Jonathan J. Lewis,et al.  PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  W. Ong,et al.  The Influence of Primary Site on Outcomes in Leiomyosarcoma: A Review of Clinicopathologic Differences Between Uterine and Extrauterine Disease , 2013, American journal of clinical oncology.

[13]  V. Torri,et al.  High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. , 2009, Radiology.

[14]  Haesun Choi,et al.  We should desist using RECIST, at least in GIST. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.